New drug trial hopes to shrink Hard-to-Treat tumors

NCT ID NCT05156866

Ongoing Disease control Sponsor: TORL Biotherapeutics, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for daily activities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma malignant pancreatic neoplasm neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR GASTRIC CANCER GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PANCREAS CANCER

Contacts and locations

Locations

Fort Wayne Medical Oncology and Hematology

Fort Wayne, Indiana, 46804, United States
Providence St. Jude Medical Center

Fullerton, California, 92835, United States
START San Antonio

San Antonio, Texas, 78229, United States
Seoul National University Bundang Hospital

Seoul, 13620, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System

Seoul, 03722, South Korea
Texas Oncology-Austin

Austin, Texas, 78705, United States
Texas Oncology-Dallas

Dallas, Texas, 75246, United States
Texas Oncology-Tyler

Tyler, Texas, 75702, United States
Torrance Memorial Medical

Torrance, California, 90505, United States
UCLA - JCCC Clinical Research Unit

Los Angeles, California, 90095, United States
Washington University School of Medicine-Siteman Cancer Center

St Louis, Missouri, 63310, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.